PPARG and Obesity: Despite the renoprotective role, the synthetic PPAR-γ agonists such as rosiglitazone, pioglitazone, and troglitazone are also reported to show various adverse effects such as fluid retention or blood volume expansion, obesity, heart disease and hepatotoxicity (Sauer, 2015).